Resultados de la búsqueda 841-850 of 15241 for disordered eating

  1. Pérdida de peso LGBTQ health - Mayo Clinic

    Hensrud DD, ed. The Mayo Clinic Diet. 3rd ed. Mayo Clinic Press; 2023. Interested in losing weight? Nutrition.gov. https://www.nutrition.gov/topics/healthy- ...

  2. Nervio facial - Mayo Clinic

    El nervio que controla los músculos faciales atraviesa un corredor angosto de hueso hasta llegar a la cara.

  3. Salud de la mujer Fitness basics - Mayo Clinic

    Mayo Clinic Q and A: What to eat for a healthy heart Feb. 03, 2025, 05:47 p.m. CDT · Mayo Clinic Minute: Alcohol and cancer risk Feb. 03, 2025, 03:58 p.m. CDT ...

  4. Neurología - Ensayos clínicos

    The goal of this research is to investigate the hypothesis that this presentation represents a spatially limited form of CNS inflammatory demyelinating disease.

  5. Pérdida de peso Más información - Mayo Clinic

    Hensrud DD, ed. The Mayo Clinic Diet. 3rd ed. Mayo Clinic Press; 2023. Interested in losing weight? Nutrition.gov. https://www.nutrition.gov/topics/healthy- ...

  6. Oncología (médica) - Ensayos clínicos

    The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't approved by the U.S. Food and Drug Administration (FDA). However ...

  7. Using fluorescence angiography to predict and prevent hypoparathyroidism after thyroid surgery - Mayo Clinic

    Using fluorescence angiography to predict and prevent hypoparathyroidism after thyroid surgery. MAC-20471898. Profesionales médicos; Using fluorescence ...

  8. Transplant Center de Mayo Clinic - Ensayos clínicos

    The purpose of this study is to compare functional improvement and caregiver burden pre- and post-liver transplant (LT) in four patient and patient's ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't approved by the U.S. Food and Drug Administration (FDA). However ...

  10. Oncología (médica) - Ensayos clínicos

    The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't approved by the U.S. Food and Drug Administration (FDA). However ...